Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innoviva Inc (NQ: INVA ) 18.41 +0.05 (+0.27%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Innoviva Inc < Previous 1 2 Next > Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress July 31, 2024 From Innoviva, Inc. Via Business Wire Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Innoviva, Inc. Via Business Wire Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress May 08, 2024 From Innoviva, Inc. Via Business Wire Innoviva to Participate in the BofA Securities Health Care Conference May 08, 2024 From Innoviva, Inc. Via Business Wire Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 April 24, 2024 From Innoviva Specialty Therapeutics Via Business Wire Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress February 29, 2024 From Innoviva, Inc. Via Business Wire Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress November 01, 2023 From Innoviva, Inc. Via Business Wire Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea November 01, 2023 From Innoviva Specialty Therapeutics Via Business Wire Innoviva to Participate in the Cantor Global Healthcare Conference September 19, 2023 From Innoviva, Inc. Via Business Wire XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults September 18, 2023 From Innoviva, Inc. Via Business Wire Innoviva Appoints Stephen Basso as Chief Financial Officer August 25, 2023 From Innoviva, Inc. Via Business Wire Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress August 02, 2023 From Innoviva, Inc. Via Business Wire Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference June 06, 2023 From Innoviva, Inc. Via Business Wire Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use May 23, 2023 From Innoviva, Inc. Via Business Wire Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases May 11, 2023 From Innoviva, Inc. Via Business Wire Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress May 09, 2023 From Innoviva, Inc. Via Business Wire Innoviva Announces Retirement of Board Chairman April 28, 2023 From Innoviva, Inc. Via Business Wire Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee April 17, 2023 From Innoviva, Inc. Via Business Wire Innoviva Stock Trading Halted Today April 17, 2023 From Innoviva, Inc. Via Business Wire Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic March 13, 2023 From Innoviva, Inc. Via Business Wire Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress February 28, 2023 From Innoviva, Inc. Via Business Wire Four Undervalued Healthcare Stocks for 2023 January 06, 2023 These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. Via MarketBeat Exposures COVID-19 Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR) November 30, 2022 From Innoviva, Inc. Via Business Wire Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress November 09, 2022 From Innoviva, Inc. Via Business Wire Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022 October 19, 2022 --- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints From Entasis Therapeutics Holdings Inc. Via GlobeNewswire Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022 October 12, 2022 Six abstracts selected for presentation, including three oral presentations From Entasis Therapeutics Holdings Inc. Via GlobeNewswire Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference September 08, 2022 From Innoviva, Inc. Via Business Wire Innoviva Completes Acquisition of La Jolla Pharmaceutical August 22, 2022 From Innoviva, Inc. Via Business Wire Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress July 27, 2022 From Innoviva, Inc. Via Business Wire Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment July 13, 2022 From Innoviva, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.